Roche announced that it will present new data across its pharmaceuticals and diagnostics portfolios at the 19^th Clinical Trials on Alzheimer’s Disease (CTAD) Congress, taking place in Boston, MA, from 16–19 November 2026.

Across 16 accepted abstracts, including two scientific symposia and two oral presentations, Roche will highlight its differentiated approach to neurodegeneration: uniting high-accuracy diagnostic testing with targeted investigational therapeutics to address the disease across its continuum.

Expanding its Alzheimer’s disease pipeline, Roche is initiating a new Phase II clinical trial, TARBELA-AD, evaluating an investigational oral NLRP3 inhibitor, RG6434, in early symptomatic Alzheimer’s disease. The study underscores Roche's multi-pronged strategy to target distinct biological mechanisms, investigating neuroinflammation as a critical driver of pathology alongside amyloid aggregation.

Scientific symposia will feature the latest research on investigational trontinemab and NLRP3 inhibition:

• Monday 16 November 16:50-17:30 ET: “Visualizing the Brainshuttle: Pioneering neuroimaging and mechanistic insights of amyloid clearance with trontinemab” will provide the latest neuroimaging, pharmacokinetics/pharmacodynamics and safety data from the Phase Ib/IIa Brainshuttle AD study, which is evaluating the potential of trontinemab to provide rapid and robust amyloid clearance in Alzheimer’s disease.
• Tuesday 17 November 14:35-15:15 ET: “Neuroinflammation in Alzheimer’s Disease: Targeting the NLRP3 Inflammasome and Neuroimmune Crosstalk” will explore neuroinflammation in Alzheimer’s disease and early data on targeting the NLRP3 inflammasome with RG6434.

Keynote address by Geoff Kerchner, Global Head of Neurodegeneration Product Development at Roche:

• Tuesday 17 November 9:10-9:35 ET: “A glimpse of the future: How diagnostics, therapies, trials, and concepts of prevention must evolve” will explore the interplay between these themes to crystallize a vision for what the future could look like, and what we need to do now to realize it.

An oral presentation will provide a deep dive into the Phase III PrevenTRON study of trontinemab in preclinical Alzheimer’s disease:

• Wednesday 18 November 9:55-10:05 ET: “PrevenTRON: Evaluating the effect of trontinemab in cognitively unimpaired individuals with biomarkers of Alzheimer’s disease at high risk of clinical decline” will detail the study design and participant screening for the PrevenTRON study, which has recently started enrolling participants.

Across multiple posters, available to view from Monday 16 November at 9:00 ET, Roche will present new clinical, health economic and real-world data for its latest blood tests, including Elecsys pTau217 and Elecsys pTau181, across diverse global patient populations and care settings to support Alzheimer’s diagnosis. Key presentations will explore the impact of integrating blood-based pTau217 testing into routine clinical practice on healthcare economics and efficiency of diagnostic pathways.

A full list of posters and presentations can be found on Roche’s website.